ArticleInternational journal of nanomedicine2026
DNA Aptamer-Functionalized Fluorescent Silica Nanoparticles: A Robust Strategy for Specific Detection and Bioimaging of HER2-Overexpressing Breast Cancer.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precise detection of HER2-positive breast cancer is vital for targeted therapy. This study integrates HER2-specific DNA aptamers with fluorescent silica nanoparticles (FSNPs) to develop a targeted imaging probe. Methods: HER2 aptamer-conjugated FSNPs (HApt-FSNPs) were synthesized and characterized. Specificity was evaluated in HER2-positive/negative cells and tumor sections via flow cytometry and microscopy. Targeting efficacy and biodistribution were assessed in tumor-bearing mice through systemic injection and real-time fluorescence imaging. Photostability and biosafety were systematically examined. Results: HApt-FSNPs showed uniform size, excellent dispersity, and enhanced photostability. They selectively bound HER2-positive cells and tumor tissues, with binding effectively blocked by free aptamer. In vivo imaging revealed specific accumulation in HER2-positive tumors, peaking at 6 hours post-injection, with minimal off-target signals. The probe demonstrated good biocompatibility in vitro and in vivo. Conclusion: The HApt-FSNP platform enables specific detection and in vivo imaging of HER2-positive breast cancer, highlighting its potential for diagnostic and bioimaging applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.